SHELBY MENARD: Open Payments
NPI 1184376592 · SOMERSWORTH, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$634 in 26 payments from 11 companies in 2025. Trend: 2023 $1,297 · 2024 $918 · 2025 $634
Food & beverage: $634
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $193 |
| Phathom Pharmaceuticals, Inc. | 2 | $164 |
| QOL Medical, LLC | 1 | $45 |
| Novo Nordisk Inc | 2 | $44 |
| Celltrion USA Inc. | 2 | $39 |
| GENZYME CORPORATION | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $25 |
| Gilead Sciences, Inc. | 1 | $24 |
| Janssen Biotech, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
Products named: VOQUEZNA, CREON, DUPIXENT, LINZESS, Sucraid, Wegovy, SKYRIZI, VEGZELMA.
Industry payments across NH — which companies pay providers there.
